LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
LGND$314.16+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
| Common Stock · Additionalpaid-incapital · Accumulatedothercomprehensiveincome (loss) · Retain earnings · Totalstockholders’equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance at December 31, 2020 | 16,080 | $16 | $318,358 | $(801) | $391,952 | $709,525 | |||
| Issuance of common stock under employee stockcompensation plans, net of shares withheld for payroll taxes | 687 | 1 | 27,744 | — | — | 27,745 | |||
| Share-based compensation | — | — | 38,783 | — | — | 38,783 | |||
| Unrealized net loss on available-for-sale securities, net of tax | — | — | — | (116) | — | (116) | |||
| Reacquisition of equity due to 2023 debt extinguishment, net of tax | — | — | (12,407) | — | — | (12,407) | |||
| Warrant and bond hedge unwind transactions | — | — | 491 | — | — | 491 | |||
| Net income | — | — | — | — | 57,138 | 57,138 | |||
| Balance at December 31, 2021 | 16,767 | 17 | 372,969 | (917) | 449,090 | 821,159 | |||
| ASU 2020-06 adoption, net of tax (Note 1) | — | — | (51,130) | — | 35,133 | (15,997) | |||
| Issuance of common stock under employee stockcompensation plans, net of shares withheld for payroll taxes | 184 | — | (5,004) | — | — | (5,004) | |||
| Share-based compensation | — | — | 60,285 | — | — | 60,285 | |||
| Unrealized net loss on available-for-sale securities, net of tax | — | — | (67) | — | (67) | ||||
| Bond hedge transaction | — | — | 202 | — | — | 202 | |||
| Distribution of OmniAb | — | — | (229,732) | — | — | (229,732) | |||
| Net loss | — | — | — | — | (33,361) | (33,361) | |||
| Balance at December 31, 2022 | 16,951 | 17 | 147,590 | (984) | 450,862 | 597,485 | |||
| Issuance of common stock under employee stockcompensation plans, net of shares withheld for payroll taxes | 605 | 1 | 17,901 | — | — | 17,902 | |||
| Share-based compensation | — | — | 25,743 | — | — | 25,743 | |||
| Unrealized net loss on available-for-sale securities, net of tax | — | — | 167 | — | 167 | ||||
| Final distribution of OmniAb | — | — | 1,665 | — | — | 1,665 | |||
| Final tax impact of OmniAb distribution | — | — | 5,797 | — | — | 5,797 | |||
| Net income | — | — | — | — | 52,154 | 52,154 | |||
| Balance at December 31, 2023 | 17,556 | $18 | $198,696 | $(817) | $503,016 | $700,913 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.